Table 8 ROC scores from the 5-fold cross-validation of the models derived from the predictive assays Model ROC score Percent inhibition cytotoxicity model 0.846 ± 0.003 IC50 cytotoxicity model 0.836 ± 0.002 Merged Percent inhibition/IC50 model 0.842 ± 0.002.
A detailed description of our experiments (including stomatal and fluorescence assays), modelling methodology, parameter fitting, model selection, sensitivity analysis, and simulations is included in the Additional file 1 that accompanies this paper.
Total 42 extracts of different parts of C. papaya were examined using key in vitro biological assay models.
In those four antioxidant assay models, Z. bungeanum polysaccharide (ZBP) displayed prominent antioxidant activities with low EC50 values of 0.011, 0.021, 0.056 and 0.008 mg/mL, respectively.
In this study 13 barley cultivars were screened for phenolic-linked functionalities targeting antioxidant and anti-hyperglycemic properties using in vitro assay models.
Participants addressed the state of the art regarding human and animal evidence for compound mediated testicular toxicity, reviewed existing alternative assay models, and brainstormed about future approaches, specifically considering tissue engineering.
The present study was designed to investigate three of our veterinary poly-herbal formulations – Phytocee™ an antistressor; Zigbir® a hepatoprotectant; and Zist® as an immunomodulator in the pertinent in vitro cell assay models in order to validate their therapeutic potential.
For studying the angiogenesis process in vitro based on endothelial cells, numerous assay models have been applied.
Briefly, for the proliferation and tube formation assay models, RPE cells were plated in Costar Transwells (Costar/Corning, NY) with 0.40 µm pore-size inserts, which were put in wells where RF/6A cells were plated.
The alternative choice is to develop other assay models with highly reproducible efficacy like in other animal models.
This assay models the later stages in successful metastasis, without the formation of a primary tumour site [ 17].
